Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-01-01 @ 4:14 AM
Study NCT ID:
NCT06454968
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-05-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Sponsor:
Peking Union Medical College Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-27
First Submit QC Date:
None
Study First Post Date:
2024-06-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-16
Last Update Post Date:
2024-06-18
Last Update Post Date Type:
ACTUAL